Enovix (NASDAQ:ENVX) Given New $7.50 Price Target at TD Cowen

Enovix (NASDAQ:ENVX) had its price objective lowered by TD Cowen from $15.00 to $7.50 in a research report sent to investors on Thursday, MarketBeat.com reports. TD Cowen currently has a hold rating on the stock.

ENVX has been the topic of a number of other reports. Canaccord Genuity Group decreased their price target on Enovix from $22.00 to $21.00 and set a “buy” rating on the stock in a research report on Thursday, November 6th. JPMorgan Chase & Co. decreased their target price on Enovix from $12.00 to $10.00 and set a “neutral” rating on the stock in a report on Wednesday, November 12th. Northland Securities set a $16.00 target price on Enovix in a research note on Monday, November 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enovix in a research report on Monday, December 29th. Finally, Cantor Fitzgerald decreased their price objective on shares of Enovix from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Enovix has a consensus rating of “Moderate Buy” and an average price target of $15.65.

Enovix Trading Down 3.3%

Shares of ENVX stock opened at $5.95 on Thursday. The firm has a fifty day moving average of $7.15 and a 200-day moving average of $8.93. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -7.73 and a beta of 2.13. Enovix has a 52-week low of $5.27 and a 52-week high of $16.49. The company has a debt-to-equity ratio of 1.74, a quick ratio of 9.47 and a current ratio of 9.72.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Caitlin John LLC acquired a new position in shares of Enovix during the 3rd quarter worth about $27,000. Parallel Advisors LLC boosted its position in Enovix by 51.9% during the third quarter. Parallel Advisors LLC now owns 3,926 shares of the company’s stock valued at $39,000 after purchasing an additional 1,342 shares during the last quarter. CWM LLC grew its stake in Enovix by 95.4% in the fourth quarter. CWM LLC now owns 6,081 shares of the company’s stock valued at $44,000 after purchasing an additional 2,969 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Enovix in the fourth quarter valued at approximately $72,000. Finally, Bowman & Co S.C. acquired a new position in shares of Enovix during the 4th quarter worth approximately $73,000. 50.92% of the stock is owned by institutional investors and hedge funds.

Enovix News Summary

Here are the key news stories impacting Enovix this week:

• Positive Sentiment: Q4 beat: Enovix reported Q4 revenue and EPS ahead of estimates (revenue ~ $11.3M; EPS -$0.14 vs. -$0.17 consensus), with strong gross‑profit improvement and year‑over‑year revenue growth. This supports continued top‑line momentum. Article Title
• Positive Sentiment: Certain analysts still maintain buy ratings despite cuts — Canaccord and Craig Hallum continue to rate ENVX a “buy,” which can limit downside from purely negative coverage. Article Title
• Neutral Sentiment: Unusual options activity: traders bought ~31,900 call options (≈+90% vs. typical daily call volume), signaling speculative bullish positioning but not necessarily fundamental conviction.
• Neutral Sentiment: Management commentary and earnings call transcript highlight revenue ramp and manufacturing issues — useful for tracking execution risk and timing of production scale‑up. Article Title
• Negative Sentiment: Weak Q1 revenue guide: Enovix issued Q1 revenue guidance ($6.5M–$7.5M) below consensus (~$8.8M), creating a near‑term revenue shortfall that likely prompted selling. See the company release/slides. Article Title
• Negative Sentiment: Analyst price‑target cuts: Multiple firms trimmed targets (Canaccord $21→$15; Craig Hallum $16→$10; TD Cowen $15→$7.50), reducing modeled upside and likely weighing on investor sentiment. Article Title
• Negative Sentiment: Balance‑sheet and liquidity concerns: cash fell materially (reported ~$106M) while total liabilities increased sharply year‑over‑year; continued cash burn and elevated liabilities raise financing and dilution risk. Insider selling was also noted. Article Title

About Enovix

Enovix Corporation (NASDAQ: ENVX) develops and manufactures advanced lithium-ion battery cells with a patented three-dimensional silicon-anode architecture. The company’s core focus is on delivering high energy density, improved safety, and longer cycle life compared to conventional graphite-based cells. Enovix’s technology targets a range of applications, including consumer electronics, wearable devices, electric vehicles and stationary energy storage systems.

Founded in 2011 and headquartered in Fremont, California, Enovix has built pilot production capability and is scaling up manufacturing capacity to meet growing demand.